gasdermin A3 Inhibitors

Gasdermin A3 inhibitors encompass a diverse group of compounds that by modulating various signaling pathways can indirectly affect the activity of Gasdermin A3. The primary mode of action for these inhibitors is not through direct interaction with Gasdermin A3, but rather through the alteration of cellular processes that are prerequisites for Gasdermin A3's role in cell death. For example, Z-VAD-FMK and Belnacasan operate by curtailing the activity of caspases, which are critical for the cleavage and subsequent activation of Gasdermin proteins, including Gasdermin A3. Inhibition of these caspases can prevent the execution of pyroptosis mediated by Gasdermin A3.

Other compounds, such as Bay 11-7082, Parthenolide, and Andrographolide, target NF-κB, a pivotal regulator of the inflammatory response that can also influence Gasdermin A3 activity. These inhibitors can decrease the transcription of pro-inflammatory cytokines and other mediators that may contribute to the activation of Gasdermin A3. Additionally, inhibitors like MCC950, which target the NLRP3 inflammasome, can reduce the activation of caspase-1, a protease that cleaves Gasdermin A3, thereby preventing its pore-forming activity. Compounds such as Disulfiram and Cyclosporin A affect the redox state of the cell and mitochondrial function, respectively, which can have secondary effects on the regulation of pyroptosis and Gasdermin A3.